Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analysesReportar como inadecuado

Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

International Journal of Bipolar Disorders

, 3:14

First Online: 24 June 2015Received: 05 March 2015Accepted: 05 June 2015


BackgroundWe aimed to establish a bipolar disorder biobank to serve as a resource for clinical and biomarker studies of disease risk and treatment response. Here, we describe the aims, design, infrastructure, and research uses of the biobank, along with demographics and clinical features of the first participants enrolled.

MethodsPatients were recruited for the Mayo Clinic Bipolar Biobank beginning in July 2009. The Structured Clinical Interview for DSM-IV was used to confirm bipolar diagnosis. The Bipolar Biobank Clinical Questionnaire and Participant Questionnaire were designed to collect detailed demographic and clinical data, including clinical course of illness measures that would delineate differential phenotypes for subsequent analyses. Blood specimens were obtained from participants, and various aliquots were stored for future research.

ResultsAs of September 2014, 1363 participants have been enrolled in the bipolar biobank. Among these first participants, 69.0 % had a diagnosis of bipolar disorder type I. The group was 60.2 % women and predominantly white 90.6 %, with a mean SD age of 42.6 14.9 years. Clinical phenotypes of the group included history of psychosis 42.3 %, suicide attempt 32.5 %, addiction to alcohol 39.1 %, addiction to nicotine 39.8 %, obesity 42.9 %, antidepressant-induced mania 31.7 %, tardive dyskinesia 3.2 %, and history of drug-related serious rash 5.7 %.

ConclusionsQuantifying phenotypic patterns of illness beyond bipolar subtype can provide more detailed clinical disease characteristics for biomarker research, including genomic-risk studies. Future research can harness clinically useful biomarkers using state-of-the-art research technology to help stage disease burden and better individualize treatment selection for patients with bipolar disorder.

KeywordsBiobank Bipolar disorder Phenotype AbbreviationsBMIbody mass index

CIRSCumulative Illness Rating Scale

SCIDStructured Clinical Interview for DSM-IV

Download fulltext PDF

Autor: Mark A Frye - Susan L McElroy - Manuel Fuentes - Bruce Sutor - Kathryn M Schak - Christine W Galardy - Brian A Palmer


Documentos relacionados